Amoytop Biotech's 2024 net profit soars 49%

Xiamen Amoytop Biotech (SSE:688278) reported a preliminary 34.13% increase in total revenue for 2024, reaching ¥281.72 million. Net profit attributable to the parent company surged by 49.00% to ¥82.76 million. Excluding non-recurring gains and losses, net profit attributable to the parent company still rose by an impressive 42.73% to ¥82.69 million. The company's basic earnings per share increased by 48.18% to ¥2.03. Total assets increased by 29.47% to ¥305.04 million, while net assets attributable to the parent company grew by 36.08% to ¥255.33 million. The company attributes this strong performance to the continued growth of its key product, PegBin, and improved operational efficiency.